BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26637849)

  • 41. Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia.
    Qi X; Zhao W; Duan Y; Li Y
    Gynecol Obstet Invest; 2008; 65(4):266-8. PubMed ID: 18196936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intrauterine Progestin Therapy as a New Approach to Premalignant Endometrial Polyps: A Prospective Observational Study.
    Sletten ET; Arnes M; Vereide AB; Ørbo A
    Anticancer Res; 2019 Sep; 39(9):4897-4903. PubMed ID: 31519593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia.
    Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009458. PubMed ID: 23737032
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study.
    Kim MK; Seong SJ; Park DC; Hong JH; Roh JW; Kang SB
    J Gynecol Oncol; 2020 Jul; 31(4):e51. PubMed ID: 32266800
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
    Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
    Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia.
    Quddus MR; Ologun BA; Sung CJ; Steinhoff MM; Lawrence WD
    Int J Gynecol Pathol; 2009 Sep; 28(5):471-6. PubMed ID: 19696618
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer.
    Monte NM; Webster KA; Neuberg D; Dressler GR; Mutter GL
    Cancer Res; 2010 Aug; 70(15):6225-32. PubMed ID: 20631067
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview.
    Varma R; Sinha D; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2006 Mar; 125(1):9-28. PubMed ID: 16325993
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
    Upson K; Allison KH; Reed SD; Jordan CD; Newton KM; Swisher EM; Doherty JA; Garcia RL
    Am J Obstet Gynecol; 2012 Jul; 207(1):36.e1-8. PubMed ID: 22727345
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term use of the levonorgestrel-releasing intrauterine system.
    Inki P
    Contraception; 2007 Jun; 75(6 Suppl):S161-6. PubMed ID: 17531611
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia.
    Ciccone MA; Whitman SA; Conturie CL; Brown N; Dancz CE; Özel B; Matsuo K
    Arch Gynecol Obstet; 2019 Mar; 299(3):801-808. PubMed ID: 30706187
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis.
    Gallos ID; Shehmar M; Thangaratinam S; Papapostolou TK; Coomarasamy A; Gupta JK
    Am J Obstet Gynecol; 2010 Dec; 203(6):547.e1-10. PubMed ID: 20934679
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reliable Identification of Endometrial Precancers Through Combined Pax2, β-Catenin, and Pten Immunohistochemistry.
    Aguilar M; Chen H; Rivera-Colon G; Niu S; Carrick K; Gwin K; Cuevas IC; Sahoo SS; Li HD; Zhang S; Zheng W; Lucas E; Castrillon DH
    Am J Surg Pathol; 2022 Mar; 46(3):404-414. PubMed ID: 34545858
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
    Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
    Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Utility of a PAX2, PTEN, and β-catenin Panel in the Diagnosis of Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia in Endometrial Polyps.
    Lucas E; Niu S; Aguilar M; Molberg K; Carrick K; Rivera-Colon G; Gwin K; Wang Y; Zheng W; Castrillon DH; Chen H
    Am J Surg Pathol; 2023 Sep; 47(9):1019-1026. PubMed ID: 37314146
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study.
    Scarselli G; Bargelli G; Taddei GL; Marchionni M; Peruzzi E; Pieralli A; Mattei A; Buccoliero AM; Fambrini M
    Fertil Steril; 2011 Jan; 95(1):420-2. PubMed ID: 20723889
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels.
    Kaunitz AM; Bissonnette F; Monteiro I; Lukkari-Lax E; DeSanctis Y; Jensen J
    Contraception; 2012 Nov; 86(5):452-7. PubMed ID: 22959906
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study.
    Barr CE; Sergeant JC; Agnew HJ; Bolton J; McVey RJ; Crosbie EJ
    BJOG; 2023 Jul; 130(8):941-948. PubMed ID: 36715558
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: single arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2006).
    Lee TS; Seong SJ; Kim JW; Ryu HS; Song ES; Nam BH
    Jpn J Clin Oncol; 2011 Jun; 41(6):817-9. PubMed ID: 21478178
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer.
    Kim MK; Seong SJ; Kim YS; Song T; Kim ML; Yoon BS; Jun HS; Lee YH
    Am J Obstet Gynecol; 2013 Oct; 209(4):358.e1-4. PubMed ID: 23791687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.